Coexpression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma
Coexpression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma
复制标题
DOI：
10.4161/cbt.5.6.2709
复制
发表时间：
2006-06-01
影响因子：
3.6
通讯作者：
Na, Yanqun
中科院分区：
文献类型：
--
作者：
Gong, Kan;Zhang, Ning;Na, Yanqun
肾透明细胞癌是最常见的肾癌，常与von Hippel-Lindau病(VHL)基因突变有关。VHL基因突变的肾小管细胞癌表现为低氧诱导因子(HIF)高表达和血管内皮生长因子(VEGF)表达增加。最近发现促红细胞生成素(EPO)在肾脏和其他与VHL疾病相关的肿瘤中表达上调。此外，EPO和EPO受体(EPOR)在这些肿瘤中也有共同表达的报道。这些结果提供了强有力的证据，表明自分泌环参与了VHL疾病的肿瘤发生。我们研究了EPO和EPOR在散发性肾细胞癌中是否也存在共表达。对54例散发性肾小管细胞癌进行分析。54例肿瘤中有30例检测到VHL基因突变。在54例肿瘤中有50例同时表达EPO和EPOR，与其VHL突变状态无关。提示EPO和EPOR的共同表达在散发性肾细胞癌的发生发展中起重要作用。
Clear cell renal cell carcinoma (CCRCC) is the most common renal carcinoma and it is often associated with von Hippel-Lindau disease (VHL) gene mutations. CCRCCs with VHL mutations demonstrate hypoxia-inducible factor (HIF) overexpression as well as increased expression of vascular endothelial growth factor ( VEGF). Recently, the erythropoietin (Epo) has been found to be upregulated in renal and other tumors associated with VHL disease. Furthermore, Epo and Epo receptor (EpoR) coexpression has also been reported in these tumors. The results provided strong evidence that an autocrine loop is involved in tumorigenesis in VHL disease. We investigated whether Epo and EpoR coexpression also occurs in sporadic CCRCC. Fifty-four sporadic CCRCCs were analyzed. VHL gene mutations were detected in 30 out of 54 tumors. Coexpression of Epo and EpoR was detected in 50 out of 54 tumors regardless of their VHL mutation status. The results suggest that coexpression of Epo and EpoR plays an important role in tumorigenesis of sporadic CCRCC.